中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

劳动节休市 04-30 16:08:13

5.420

-0.040

-0.73%

最高5.490	最低5.410	成交量6,645万
今开5.420	昨收5.460	日振幅1.47%
总市值1,016亿	流通市值1,016亿	总股本187.45亿
成交额3.61亿	换手率0.35%	流通股本187.45亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":5.42,"timestamp":1777536493003,"preClose":5.46,"halted":0,"volume":66447181,"delay":0,"changeRate":-0.007326007326007333,"floatShares":18745000000,"shares":18745000000,"eps":0.14878834643282365,"marketStatus":"劳动节休市","change":-0.04,"latestTime":"04-30 16:08:13","open":5.42,"high":5.49,"low":5.41,"amount":361188900,"amplitude":0.014652,"askPrice":5.44,"askSize":1396000,"bidPrice":5.42,"bidSize":676000,"shortable":3,"etf":0,"ttmEps":0.14878834643282365,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777858200000},"marketStatusCode":7,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":5.46,"dividendRate":0.019048,"openAndCloseTimeList":[[1777512600000,1777521600000],[1777525200000,1777536000000]],"volumeRatio":0.8560192172199994,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.3693,"impliedVolPercentile":0.2276},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"1103407305","title":"中国生物制药：4月30日回购185.00万股，耗资约1,003.20万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103407305","media":"公告速递","labels":[],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103407305?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:57","pubTimestamp":1777539428,"startTime":"0","endTime":"0","summary":"2026年4月30日，中国生物制药有限公司公布一则股份购回公告。公告显示，公司于当日回购普通股合共1,850,000股，约占公司已发行股本的0.01%。此次回购价格区间介乎每股5.42港元至5.43港元，涉资总额约10,031,995港元。回购完成后，公司已发行股份总数维持在18,745,367,230股，库藏股数为0。截至目前，已通过香港联交所或其他证券交易所累计回购31,520,000股，占该授权决议获通过当日公司已发行股份总数约0.168%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药：4月30日回购185.00万股，耗资约1,003.20万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631575455","title":"中国生物制药获副主席郑翔玲增持100万股 每股作价约5.47港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2631575455","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631575455?lang=zh_cn&edition=full","pubTime":"2026-04-30 08:04","pubTimestamp":1777507440,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新数据显示，4月29日，副主席郑翔玲增持中国生物制药（01177）100万股，每股作价5.4705港元，总金额为547.05万港元。增持后最新持股数目约为29.73亿股，持股比例为15.86%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-04-30/doc-inhwfpqn7268988.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1191","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","EWH","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1521","BK1589","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130464578","title":"中国生物制药4月29日回购183万股，涉资约1,000.88万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1130464578","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130464578?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:19","pubTimestamp":1777454377,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司于2026年4月29日公告，于香港联合交易所场内回购普通股1,830,000股，占公司于相关事件前现有已发行股本的约0.01%。回购价格介乎每股5.46港元至5.47港元之间，合计支付约1,000.88万港元。本次回购完成后，公司已发行股本仍为18,745,367,230股，库藏股数为0股。截至目前，在香港联交所或其他证券交易所累计已回购股份29,670,000股，占该购回授权通过当天已发行股本总数约0.158%。公告由公司秘书赖娟签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"中国生物制药4月29日回购183万股，涉资约1,000.88万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631664593","title":"中国生物制药(01177)4月29日斥资1000.88万港元回购183万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2631664593","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631664593?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:16","pubTimestamp":1777454178,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2026年4月29日斥资1000.88万港元回购183万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1589","01177","BK1191","HK0000165453.HKD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1521","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191064912","title":"中国生物制药(01177)2025年收入同比增长10.3%，加速创新药与国际化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1191064912","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191064912?lang=zh_cn&edition=full","pubTime":"2026-04-29 16:58","pubTimestamp":1777453102,"startTime":"0","endTime":"0","summary":"中国生物制药主要从事创新研发驱动型医药业务，覆盖生物制药与研发、品牌药品生产与销售，产品线涵盖肿瘤、肝病、心血管代谢、外科镇痛、呼吸、自身免疫等多个治疗领域，形成从“研究—制造—销售”的完整产业链。根据公司主席报告，集团于截至2025年12月31日止年度取得收入约人民币318.3亿元，较去年同期增长约10.3%。2025年季度层面，第一季度归属于母公司持有者的净利润为5.95亿元人民币，同比大幅减少84.0%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药(01177)2025年收入同比增长10.3%，加速创新药与国际化布局","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151429103","title":"中国生物制药：田舟山卸任董事后仍将担任管理职务","url":"https://stock-news.laohu8.com/highlight/detail?id=1151429103","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151429103?lang=zh_cn&edition=full","pubTime":"2026-04-29 16:56","pubTimestamp":1777452993,"startTime":"0","endTime":"0","summary":"中国生物制药（01177.HK）宣布，田舟山先生将卸任公司董事职务，但会继续保留管理职能。这一人事变动体现了公司治理结构的优化调整，旨在实现决策层与执行层的合理分工。\n田舟山在医药行业拥有丰富的管理经验，其继续参与公司日常运营管理，将有助于保持企业战略的连贯性和执行力。中国生物制药作为国内领先的医药企业，此次人事安排也反映出公司对管理团队稳定性的重视。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YT58.USD","BK1589","HK0000165453.HKD","BK1515","IE00BZ08YR35.GBP","BK1521","IE00BZ08YS42.EUR","01177","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190924998","title":"中国生物制药授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1190924998","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190924998?lang=zh_cn&edition=full","pubTime":"2026-04-29 16:55","pubTimestamp":1777452951,"startTime":"0","endTime":"0","summary":"中国生物制药于2026年4月29日发布公告，董事会计划在即将召开的股东周年大会上就股份购回授权寻求股东批准。根据公告，授权范围最高可达公司于相关会议日期已发行股份总数的10%，即最多约1,874,536,723股。该公司现有已发行股份数约18,745,367,230股，拟以可分配收益作为购回资金来源，并严格遵循香港上市规则及开曼群岛相关法律条款。董事会表示，此次回购意在提升股东回报和维护公司整体利益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631598826","title":"中国生物制药(01177)：田舟山退任执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2631598826","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631598826?lang=zh_cn&edition=full","pubTime":"2026-04-29 16:52","pubTimestamp":1777452725,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，田舟山及李大魁已知会本公司，彼等各自将分别退任执行董事及独立非执行董事之职务，自2026年股东周年大会结束起生效，且不会膺选连任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","HK0000165453.HKD","BK1521","BK1589","BK1191","BK1515","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631558184","title":"中国生物制药获副主席郑翔玲增持300万股 每股作价约5.43港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2631558184","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631558184?lang=zh_cn&edition=full","pubTime":"2026-04-29 08:03","pubTimestamp":1777420980,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新数据显示，4月28日，副主席郑翔玲增持中国生物制药（01177）300万股，每股作价5.4282港元，总金额为1628.46万港元。增持后最新持股数目约为29.72亿股，持股比例为15.85%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-04-29/doc-inhwckrm1108572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BZ08YS42.EUR","BK1191","01177","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1521","IE00BZ08YT58.USD","BK1515","EWH","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138155346","title":"中国生物制药4月28日回购365.00万股，耗资约2,005.02万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1138155346","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138155346?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:57","pubTimestamp":1777366621,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司  于2026年4月28日发布翌日披露报表，公告进行股份购回。该公司于4月28日回购3,650,000股普通股，约占现有已发行股本的0.019%。每股回购价格介乎港币5.41元至5.56元，合计付出约2,005.02万港元。公告显示，本次回购后公司已发行股本仍为18,745,367,230股，库藏股数为0股。此前公司于2025年6月10日通过回购授权，可回购股份总数为1,876,071,723股，截至目前，已根据授权累计购回27,840,000股，占通过授权当日已发行股本的0.148%。本次公告由公司秘书赖娟签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药4月28日回购365.00万股，耗资约2,005.02万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630769173","title":"中国生物制药(01177)：康晓燕已获委任为首席医学官","url":"https://stock-news.laohu8.com/highlight/detail?id=2630769173","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630769173?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:36","pubTimestamp":1777365378,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，康晓燕博士已获本公司委任为首席医学官，刘蒙博士已获本公司委任为慢病领域临床开发负责人，刘荣军博士已获本公司委任为自身免疫疾病(自免)领域临床开发负责人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435232.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","01177","BK1191","BK1515","BK1521","IE00BZ08YS42.EUR","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119743340","title":"中国生物制药4月27日回购181万股股份，耗资约1004.73万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119743340","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119743340?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:02","pubTimestamp":1777280564,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司于2026年4月27日向香港联交所提交翌日披露报表，宣布当日于港交所场内回购普通股181万股，占公司已发行股本约0.01%。回购价格区间为每股5.54港元至5.57港元，合计支付约1004.73万港元。上述购回股份截至目前尚未注销，因此公司已发行股本仍维持18,745,367,230股，库藏股数为0股。公司于当天再次确认，其股份回购行为符合香港联合交易所有限公司证券上市规则及相关法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药4月27日回购181万股股份，耗资约1004.73万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630369342","title":"中国生物制药(01177)4月27日斥资1004.73万港元回购181万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630369342","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630369342?lang=zh_cn&edition=full","pubTime":"2026-04-27 16:56","pubTimestamp":1777280186,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2026年4月27日，该公司斥资1004.73万港元回购181万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","IE00BZ08YS42.EUR","BK1589","IE00BZ08YT58.USD","BK1521","HK0000165453.HKD","BK1515","IE00BZ08YR35.GBP","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135919559","title":"中国生物制药：4月24日回购178万股，耗资约1008.90万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135919559","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135919559?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:04","pubTimestamp":1777021444,"startTime":"0","endTime":"0","summary":"中国生物制药（股票代码：01177）于2026年4月24日进行股份回购，涉及178万股普通股，占公司已发行股本约0.009%。每股回购价介乎5.65港元至5.69港元，总金额约1008.90万港元。\n公告显示，公司于上述回购完成后，已发行股本仍为18,745,367,230股。根据2025年6月10日通过的购回授权，公司可回购股份总数为1,876,071,723股，截至目前已累计回购22,380,000股。公司方面确认本次回购符合相关上市规则及法例要求。\n本公告由公司秘书赖娟签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药：4月24日回购178万股，耗资约1008.90万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629361811","title":"中国生物制药(01177)4月24日斥资1008.9万港元回购178万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629361811","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629361811?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:01","pubTimestamp":1777021273,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2026年4月24日该公司斥资1008.9万港元回购178万股，回购价格为每股5.65-5.69港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","BK1191","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1515","BK1589","01177","IE00BZ08YR35.GBP","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182441065","title":"中国生物制药4月23日回购180万股股份，涉资约1,005.48万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182441065","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182441065?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:47","pubTimestamp":1776934047,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司于2026年4月23日发布公告，披露当日在香港联交所回购180万股普通股份，占已发行股本约0.01%。本次回购价格介乎每股5.58港元至5.60港元，总涉资约1,005.48万港元。公告显示，回购完成后，公司已发行股本仍为18,745,367,230股，库藏股数量保持为0股。截至公告日，累计已回购股份数为20,600,000股，占回购授权决议通过当日公司已发行股本的约0.11%。公司确认已遵守香港联合交易所有限公司的相关上市规则及法定程序，公告由公司秘书赖娟签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药4月23日回购180万股股份，涉资约1,005.48万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101961182","title":"中国生物制药4月22日回购172万股，涉资约1,002.38万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101961182","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101961182?lang=zh_cn&edition=full","pubTime":"2026-04-22 17:27","pubTimestamp":1776850068,"startTime":"0","endTime":"0","summary":"2026年4月22日，中国生物制药公告显示，公司于当日于香港联交所场内回购1,720,000股普通股，占已发行股本约0.009%。本次回购每股价格介乎5.82港元至5.84港元，总金额约10,023,816港元，折合约1,002.38万港元。本次回购根据2025年6月10日通过的购回授权进行，授权可回购股份总数为1,876,071,723股，截至目前已累计回购18,800,000股，占授权通过当日已发行股本约0.1%。公司确认上述回购行为已遵守香港联合交易所有限公司证券上市规则及相关法律法规。公告由公司秘书赖娟签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药4月22日回购172万股，涉资约1,002.38万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629199710","title":"中国生物制药(01177)4月22日斥资1002.38万港元回购172万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629199710","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629199710?lang=zh_cn&edition=full","pubTime":"2026-04-22 17:22","pubTimestamp":1776849734,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2026年4月22日该公司斥资1002.38万港元回购172万股，回购价格为每股5.82-5.84港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","BK1515","IE00BZ08YS42.EUR","BK1191","IE00BZ08YR35.GBP","BK1589","HK0000165453.HKD","01177","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629067858","title":"中国生物制药附属自主研发LM-364、LM-338公布研究数据，计划2026年启动首次人体试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2629067858","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629067858?lang=zh_cn&edition=full","pubTime":"2026-04-22 09:05","pubTimestamp":1776819900,"startTime":"0","endTime":"0","summary":"4月22日，中国生物制药（01177）发布公告，旗下全资附属公司礼新医药科技（上海）有限公司自主研发的两款新一代抗体偶联药物LM-364和LM-338，于2026年美国癌症研究协会年会公布最新研究数据。LM-364针对肿瘤微环境中的Nectin-4靶点，显示出在高浓度ANP条件下的优越药物内化与毒素释放能力，显著降低对正常组织的毒性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223713432933.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1521","IE00BZ08YT58.USD","BK1589","IE00BZ08YS42.EUR","BK1191","01177","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629906669","title":"中国生物制药(01177)：礼新医药于AACR 2026公布两款ADC最新研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629906669","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629906669?lang=zh_cn&edition=full","pubTime":"2026-04-22 06:16","pubTimestamp":1776809789,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 公布，该集团全资附属公司礼新医药科技(上海)有限公司自主研发的两款新一代抗体偶联药物 LM-364 “Nectin-4TME ADC”及LM-338 “STn ADC”，于2026年美国癌症研究协会年会公布最新研究数据。LM-364是礼新医药依托自主开发的肿瘤微环境平台开发的新一代Nectin-4TME ADC。目前，LM-364已向美国食品药品监督管理局递交新药临床试验申请，计划于2026年启动首次人体临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","BK1515","BK4231","IE00BZ08YT58.USD","BK1589","09939","ADC","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","159938","BK1191","01177","HK0000165453.HKD","BK1574","BK4080","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":-0.0304},{"period":"1month","weight":-0.0798},{"period":"3month","weight":-0.1837},{"period":"6month","weight":-0.2334},{"period":"1year","weight":0.4052},{"period":"ytd","weight":-0.123}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0399},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.005},{"period":"1year","weight":0.1653},{"period":"ytd","weight":0.0057}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.008254},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056687},{"month":3,"riseRate":0.565217,"avgChangeRate":0.045006},{"month":4,"riseRate":0.478261,"avgChangeRate":0.021296},{"month":5,"riseRate":0.727273,"avgChangeRate":0.043347},{"month":6,"riseRate":0.363636,"avgChangeRate":0.00957},{"month":7,"riseRate":0.636364,"avgChangeRate":0.047691},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.010062},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.015174},{"month":10,"riseRate":0.545455,"avgChangeRate":0.025184},{"month":11,"riseRate":0.5,"avgChangeRate":0.066781},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.01175}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SBP GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}